Terns Pharmaceuticals, Inc. (TERN) Financial Statements (2025 and earlier)

Company Profile

Business Address 1065 EAST HILLSDALE BLVD., SUITE 100
FOSTER CITY, CA 94404
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments358,164263,440283,114165,982
Cash and cash equivalent161,43979,926143,23547,699
Short-term investments196,725183,514139,879118,283
Other undisclosed current assets3,9453,9922,071948
Total current assets:362,109267,432285,185166,930
Noncurrent Assets
Operating lease, right-of-use asset1,2485231,047 
Property, plant and equipment2225067571,046
Other noncurrent assets350563794
Total noncurrent assets:1,8201,0851,8411,140
TOTAL ASSETS:363,929268,517287,026168,070
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11,8349,3316,5985,250
Employee-related liabilities2,403
Accounts payable2,1482,5151,6452,126
Accrued liabilities9,6866,8164,953721
Other undisclosed current liabilities3,8162,6131,8701,570
Total current liabilities:15,65011,9448,4686,820
Noncurrent Liabilities
Liabilities, other than long-term debt2,4091,2061,615947
Accounts payable and accrued liabilities1,4901,2061,071787
Deferred rent credit    160
Operating lease, liability919 544 
Total noncurrent liabilities:2,4091,2061,615947
Total liabilities:18,05913,15010,0837,767
Equity
Equity, attributable to parent345,870255,367276,943160,303
Common stock9653
Additional paid in capital767,621588,008520,178342,711
Accumulated other comprehensive loss(279)(19)(822)(338)
Accumulated deficit(421,481)(332,628)(242,418)(182,073)
Total equity:345,870255,367276,943160,303
TOTAL LIABILITIES AND EQUITY:363,929268,517287,026168,070

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenues    1,000
Gross profit:    1,000
Operating expenses(101,871)(102,558)(62,029)(50,860)
Operating loss:(101,871)(102,558)(62,029)(49,860)
Nonoperating income13,27812,5872,042210
Investment income, nonoperating13,28912,9012,110170
Other nonoperating income (expense)(11)(314)(68)40
Loss from continuing operations before income taxes:(88,593)(89,971)(59,987)(49,650)
Income tax expense(260)(239)(358)(508)
Loss from continuing operations:(88,853)(90,210)(60,345)(50,158)
Loss before gain (loss) on sale of properties:(50,158)
Net loss available to common stockholders, diluted:(88,853)(90,210)(60,345)(50,158)

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Net loss:(88,853)(90,210)(60,345)(50,158)
Comprehensive loss:(88,853)(90,210)(60,345)(50,158)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(260)803(484)(214)
Comprehensive loss, net of tax, attributable to parent:(89,113)(89,407)(60,829)(50,372)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: